Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 20:8:313.
doi: 10.3389/fendo.2017.00313. eCollection 2017.

Optimizing Patient Management and Adherence for Children Receiving Growth Hormone

Affiliations

Optimizing Patient Management and Adherence for Children Receiving Growth Hormone

Carlo L Acerini et al. Front Endocrinol (Lausanne). .

Abstract

Poor adherence with growth hormone (GH) therapy has been associated with worse clinical outcomes, which in children relates specifically to their linear growth and loss of quality of life. The "360° GH in Europe" meeting, held in Lisbon, Portugal, in June 2016 and funded by Merck KGaA (Germany), examined many aspects of GH diseases. The three sessions, entitled "Short Stature Diagnosis and Referral," "Optimizing Patient Management," and "Managing Transition," each benefited from three guest speaker presentations, followed by an open discussion and are reported as a manuscript, authored by the speakers. Reported here is a summary of the proceedings of the second session, which reviewed the determinants of GH therapy response, factors affecting GH therapy adherence and the development of innovative technologies to improve GH treatment in children. Response to GH therapy varies widely, particularly in regard to the underlying diagnosis, although there is little consensus on the definition of a poor response. If the growth response is seen to be less than expected, the possible reasons should be discussed with patients and their parents, including compliance with the therapy regimen. Understanding and addressing the multiple factors that influence adherence, in order to optimize GH therapy, requires a multi-disciplinary approach. Because therapy continues over many years, various healthcare professionals will be involved at different periods of the patient's journey. The role of the injection device for GH therapy, frequent monitoring of response, and patient support are all important for maintaining adherence. New injection devices are incorporating electronic technologies for automated monitoring and recording of clinically relevant information on injections. Study results are indicating that such devices can at least maintain GH adherence; however, acceptance of novel devices needs to be assessed and there remains an on-going need for innovations.

Keywords: adherence; digital health; endocrinology; growth hormone administration devices; pediatric growth hormone response; personalized medicine.

PubMed Disclaimer

References

    1. Maghnie M, Labarta JI, Koledova E, Rohrer TR. Short stature diagnosis and referral. Front Endocrinol (Lausanne) (2017). - PMC - PubMed
    1. Hauffa BP, Touraine P, Urquhart T, Koledova E. Managing transition in patients treated with growth hormone. Front Endocrinol (Lausanne) (2017). - PMC - PubMed
    1. Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A, et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr (2011) 75:335–45.10.1159/000322878 - DOI - PubMed
    1. Savage MO, Burren CP, Rosenfeld RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf) (2010) 72:721–8.10.1111/j.1365-2265.2009.03775.x - DOI - PubMed
    1. Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab (2008) 93:352–7.10.1210/jc.2007-1581 - DOI - PubMed

LinkOut - more resources